Enhance clinical trial adherence with PerfPak® Advantage

WestRock's newest addition to its suite of clinical trial solutions

Convenient and discreet size allows greater freedom

This integrated blister and wallet card uses WestRock's unique child-resistance mechanism to offer a package that's convenient and more appealing to patients. PerfPak Advantage's design provides flexibility with various dosing regimens for a wide variety of clinical trial requirements.

Printed calendar for dosage tracking improves medication adherence

Child-resistance is based in the individual pill cavities



Readable, flat space for educational information about the medication and the importance of adherence

Built on a legacy of senior-friendly, child-resistant packaging

Instead of force, PerfPak uses cognitive technique for opening – which studies show consumers prefer. WestRock has the most medication packages that have passed the Consumer Product Safety Commission's CR testing at the highest level. PerfPak Advantage has met the CPSC CR standard for an F=1 rating while also being senior-friendly.

WestRock

PerfPak® Advantage

Patient-centric design provides medication information from every angle



Medication information and dosing instructions on the front of PerfPak Advantage allows for easy use for patients and encourages medication adherence. Ample billboard space for required labels and multi-language instructions if needed.

Unique integrated child-resistance mechanism in every pill cavity.

Reduce risk and secure supply with WestRock's global supply chain

Integrated into our existing global supply chain, this package is quickly available with short lead times because of manufacturing capabilities in US and Europe as well as rapid-response timelines. We have the ability to offer unique service level agreements, ensuring security of supply and reducing risk.

- **The main reason for delay or denial of FDA approval is uncertainty related to dose selection[1]**
- **Adherence data collected during clinical trials could provide valuable information for safety, efficacy and optimal dose response curves**

1. Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs. *JAMA*. 311(4). 2014.

Contact us:
healthcare@WestRock.com
+1 800 864 2685

WestRock

WestRock.com